MiMedx Group
Trial Pipeline
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
NCT06600724
Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee
NCT03485157
Use of Human Dehydrated Amnion Chorion Allograft in Closed Hemorroidectomy
NCT03479489
Micronized dHACM Injectable for the Treatment of Plantar Fasciitis
NCT02427191
dHACM in Lumbar Decompression and Microdiscectomy Surgery
NCT02300909
Amniotic Membrane in Total Knee Replacements to Reduce Scarring
NCT02088567
Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis
NCT01659827
Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
NCT01552499
Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers
NCT01552447
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What the Pipeline for MiMedx Group Shows
According to the ClinicalTrials.gov registry, MiMedx Group is linked to 9 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 11% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 89% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for MiMedx Group reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for MiMedx Group is Scarring with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.